Pharmaceuticals

Ranibizumab Market Size and Demand Forecast 2026–2030

February 24, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the ranibizumab market from 2026–2035 with trusted insights from The Business Research Company

What upper market value could the Ranibizumab Market reach by 2030 starting from 2026 levels?

The ranibizumab market size has experienced consistent expansion over recent years. It is projected to increase from $2.76 billion in 2025 to $2.87 billion in 2026, exhibiting a compound annual growth rate (CAGR) of 4.0%. Historically, this market’s growth can be attributed to the rising prevalence of age-related macular degeneration, the clinical validation of anti-VEGF therapy efficacy, an increasing incidence of diabetic retinopathy, improved diagnostic imaging for retinal disorders, and early regulatory approvals for ranibizumab.

The ranibizumab market is anticipated to experience consistent expansion over the upcoming years. Its valuation is projected to reach $3.31 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 3.6%. This predicted growth is primarily driven by factors such as a global increase in the aging population, the escalating prevalence of diabetes worldwide, enhanced availability of sophisticated ophthalmic treatments, a greater uptake of intravitreal injections, and continuous advancements in programs for screening retinal diseases. Key developments anticipated during this timeframe involve a surging acceptance of anti-VEGF therapies for various retinal ailments, an increasing demand for prefilled syringe formulations, a rising need for treating diabetic eye conditions, the establishment of more specialized ophthalmology care facilities, and a greater application of sustained maintenance therapy for persistent retinal conditions.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=16172&type=smp

Which Drivers Are Influencing Long-Term Growth In The Ranibizumab Market?

The rising occurrence of ocular conditions is projected to stimulate the expansion of the ranibizumab market moving forward. Ocular conditions encompass a variety of ailments affecting the eyes, which can potentially diminish vision and overall eye health. The increasing incidence of eye diseases stems from factors such as an aging populace and shifts in lifestyle, alongside an uptick in chronic ailments like diabetes. Ranibizumab is utilized to manage conditions such as age-related macular degeneration and diabetic retinopathy, aiding in the reduction of vision impairment amidst the growing prevalence of eye diseases. For example, in August 2023, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that roughly 2.2 billion individuals worldwide experience either near or distance vision impairment. Therefore, the increasing prevalence of eye diseases will propel the growth of the ranibizumab market.

How Is The Ranibizumab Market Divided Into Segments?

The ranibizumab market covered in this report is segmented –

1) By Product: Single Use Prefilled Syringe, Single Use Glass Vial

2) By Application: Wet Age Related Macular Degeneration (AMD), Diabetic Retinopathy (DR), Diabetic Macular Edema (DME), Myopic Choroidal Neovascularization (MCNV), Retinal Vein Occlusion (RVO)

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Other Distribution Channels

Subsegments:

1) By Single Use Prefilled Syringe: 0.3 Ml Syringe, 0.5 Ml Syringe, 1 Ml Syringe, Other Volume Variants

2) By Single Use Glass Vial: 0.5 Mg Or 0.05 Ml Vial, 1.0 Mg Or 0.1 Ml Vial, 2.0 Mg Or 0.2 Ml Vial, Other Volume Variants

Which Trends Are Influencing The Development Of The Ranibizumab Market?

Companies prominently involved in the ranibizumab market are prioritizing economical treatments, such as ranibizumab biosimilars, to manage and prevent vision impairment in individuals with retinal disorders. A biosimilar of ranibizumab is a biological medicine that closely mirrors the original ranibizumab but is distributed under a distinct brand name, providing a more accessible financial option while maintaining comparable effectiveness and safety profiles. For instance, in April 2024, Formycon AG, a Germany-based biotechnology company, and Bioeq AG, a Switzerland-based biopharmaceutical company, announced the commercial introduction of FYB201, a biosimilar to Lucentis (Ranibizumab), in Canada and Switzerland. This launch follows the marketing approval granted by Health Canada under the brand name Ranopto and Swissmedic under the brand name Ranivisio. FYB201 provides a fresh, superior quality, potent, and budget-friendly treatment alternative for patients dealing with severe retinal conditions. It has already shown its importance as an affordable treatment selection for patients in the USA and various regions of Europe.

Which Leading Companies Dominate The Ranibizumab Market Share?

Major companies operating in the ranibizumab market are F. Hoffmann-La Roche AG, Genentech Inc., Bayer AG, Novartis AG, Biocon Limited, Samsung Biologics Co Ltd, Celltrion Healthcare Co Ltd, Formycon AG, Coherus BioSciences Inc, Xbrane Biopharma AB, Alvotech, Stada Arzneimittel AG, Sun Pharmaceutical Industries Ltd, Dr. Reddy’s Laboratories Ltd, Cipla Limited, Lupin Limited, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd, Enzene Biosciences Ltd, Amman Pharmaceutical Industries

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

How Does The Ranibizumab Market Perform Across Major Global Regions?

North America was the largest region in the ranibizumab market in 2025. The regions covered in the ranibizumab market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Ranibizumab Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=16172&type=smp

Browse Through More Reports Similar to the Global Ranibizumab Market 2026, By The Business Research Company

Ranibizumab Market Report 2026

https://www.thebusinessresearchcompany.com/report/ranibizumab-global-market-report

Ibrutinib Market Report 2026

https://www.thebusinessresearchcompany.com/report/ibrutinib-global-market-report

Takaful Market Report 2026

https://www.thebusinessresearchcompany.com/report/takaful-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795